More on BEAM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $29.41 |
|
|||
| Open | $29.46 | ||||
| 52 Wk High | $83.60 | ||||
| 52 Wk Low | $82.96 | ||||
| Day High | $30.50 | ||||
| Day Low | $28.88 | ||||
| P/E | 12.92 | ||||
| EPS | $2.24 | ||||
| Volume | 860,719 | ||||
- Form 8-K Beam Therapeutics Inc. For: Jun 03
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: MARAGANORE JOHN
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Shaw Christi
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Walsh Kathleen E
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Guindo Chirfi
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: COOPER GRAHAM K
- Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Fishman Mark
- H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
- Beam Therapeutics presents BEAM-302 data at conference
- Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Entities mentioned with BEAM
- Earnings | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Show More...
